Barbara A. Helfrich
University of Colorado Anschutz · 100 works · 3,214 citations · h-index 24
Top works
- Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines
- Epidermal growth factor receptor family in lung cancer and premalignancy
- Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non–small cell lung carcinoma
- Fibroblast Growth Factor (FGF) and FGF Receptor-Mediated Autocrine Signaling in Non-Small-Cell Lung Cancer Cells
- ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer
- Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non–Small Cell Lung Cancer Cell Lines
- Antitumor Activity of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Gefitinib (ZD1839, Iressa) in Non–Small Cell Lung Cancer Cell Lines Correlates with Gene Copy Number and EGFR Mutations but not EGFR Protein Levels
- Altered HOX and WNT7A expression in human lung cancer
- Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
- ZEB1-responsive genes in non-small cell lung cancer
- FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
- Reversal of anticancer multidrug resistance by the ardeemins
- Tankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition
- Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors.
- Discordant Signal Transduction and Growth Inhibition of Small Cell Lung Carcinomas Induced by Expression of GTPase-deficient Gα16
- Native and rearranged ALK copy number and rearranged cell count in non–small cell lung cancer
- Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo
- Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a “biased agonist” mechanism
- Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth.
- Preclinical Studies of Gemcitabine and Trastuzumab in Breast and Lung Cancer Cell Lines